Latest Compliance News

Auking Mining’s planned acquisition of Orion Resources has hit a regulatory roadblock, while Orion’s purchase of the Cloncurry Gold Project assets faces settlement delays due to vendor conditions.

SportsHero Limited has voluntarily suspended trading on the ASX pending a Supreme Court decision regarding its failure to lodge required cleansing notices for recent share issues.

Encounter Resources has completed the first tranche of its $25 million share placement, raising approximately $24.5 million to advance its mineral exploration projects. The second tranche, involving shares to a company director, awaits shareholder approval.

Mount Hope Mining has issued over six million shares via placement and is set to offer additional shares through a share purchase plan, signaling a strategic capital raise.

Bentley Capital Limited has addressed a sharp 70% rise in its share price and a spike in trading volume, attributing the movement to ongoing legal proceedings rather than undisclosed information.

Tivan Limited has confirmed ultra high-grade fluorite mineralisation at its newly acquired Molyhil Project, with assays reaching up to 85.9% CaF2. This discovery complements imminent drilling activities at the adjacent Sandover Fluorite Project, positioning Tivan for a significant expansion in its critical minerals portfolio.

Sweden’s Parliament has voted to overturn its uranium mining ban, effective January 2026, paving the way for Aura Energy to fully develop its polymetallic Häggån project with uranium extraction now permitted.

Arafura Rare Earths secures an ASX waiver allowing eligible shareholders to vote on its upcoming Share Purchase Plan, ensuring broader participation in a key capital raising step.

National Australia Bank reported a 1% increase in underlying profit for FY25, with strong deposit growth and higher credit impairment charges marking the year. The bank maintained solid capital ratios and announced an 85 cent fully franked dividend.

Immuron Limited has secured FDA approval for its IMM-529 Investigational New Drug application, clearing the way for a Phase 2 clinical trial targeting Clostridioides difficile infection. This milestone marks a significant step forward for a novel oral antibody therapy addressing a critical infectious disease with high recurrence rates.

4DMedical has responded to ASX queries over its FY2025 financial report, clarifying assumptions behind intangible asset valuations and addressing the auditor’s qualified opinion.

PEXA Group reported a robust first quarter for FY26, driven by refinancing growth in Australia and rising momentum in the UK market. The company reaffirmed its full-year guidance while advancing key strategic initiatives including platform modernization and a NatWest partnership.